Dashboard


Animal Drug Compounding Market is set to witness healthy growth at a CAGR of 8% over the forecast period of 2021-2031

2022-04-06 00:30:00 - Pune, Maharashtra, India - (PR Distribution™)

New York:  Scarce availability of FDA-approved drug formulations for diseases in animals is mended through animal drug compounding, with varied formulations and administration of desired active ingredients. Furthermore, compounded animal drugs are available in alternate dosage forms and dosage strengths, unlike branded veterinary drugs that often come in a single dosage or strength.

Many drugs contain flavoured formulations for the purpose of increasing palatability and compliance. This is done by changing the gritty texture into a smooth and creamy consistency. Abnormal limb coordination, seizures, behavioural changes and blindness in animals such as dogs and cats is commonly observed. CNS drugs are most frequently dispensed in order to treat neurological disorders in animals, and account for the highest demand as far as animal drug compounding is concerned.

Persistence Market Research predicts that the global market for animal drug compounding will be valued at close to US$ 1.9 Bn in 2021, and expand at an 8% CAGR over the forecast period (2021-2031).

Get sample PDF of report: https://www.persistencemarketresearch.com/samples/12871 

Key Takeaways from Market Study

  • The global market for animal drug compounding is projected to expand 2X over the next ten years.
  • Manipulation of animal moods and emotions through hormones and substitutes is expected to aid market growth over the coming years.
  • Oral formulations are set to dominant the market share at around 80% by 2031.
  • Increasing awareness about the medical needs of companion pets is expected to contribute to market growth.
  • The region of North America dominates the global animal drug compounding market, and is expected to retain its top position over the forecast period as well.
  • The market in the U.S. is expected to progress at around 8% CAGR through 2031, while that in the U.K. is projected to expand at around 10% over the decade.

Know the methodology of report by asking an expert: https://www.persistencemarketresearch.com/ask-an-expert/12871 

“Unavailability of commercially produced branded drugs in the market with specific and desired formulations is set to fuel demand for compounded drug formulations over the years to come” says the PMR analyst

CNS Drugs Remain Highly Attractive

Central nervous system inflammation in companion animals such as dogs and cats is highly common and results in several neurological disorders. This can result in behavioural changes, seizures, blindness, and abnormal limb coordination. Incorporation of CNS agents in compounded drugs for animals can effectively be helpful in the treatment of nervous abnormalities in them. As such, the CNS agents segment holds around 36% share in the global market for animal drug compounding, in terms of product.

Get full access of report: https://www.persistencemarketresearch.com/checkout/12871 

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the animal drug compounding market in its latest study, presenting historical demand assessment of 2016 – 2020and projections for 2021 – 2031. The research study is based on product (CNS agents, anti-infective agents, hormones and substitutes, anti-inflammatory agents, and others), animal (companion animals and livestock animals), and formulation (oral, injectable, and others), across seven key regions of the world (North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa.

Browse End-to-end Market:  Healthcare

Related Reports:



About Persistence Market Research 

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact

Rajendra Singh 

Persistence Market Research 

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA - Canada Toll-Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Visit Our Website: 

https://www.persistencemarketresearch.com

Media Contacts:


Full Name
Kalyani Badkas
Company
Persistence Market Research
Phone Number
+1-646-568-7751
Email
View Results in Google